Zhejiang Tianyu Pharmaceutical Co.,Ltd. (SHE: 300702) has announced that its active pharmaceutical ingredient for brivaracetam has recently passed the review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.

This pharmaceutical is indicated for the adjunctive treatment of partial-onset seizures, particularly for patients who show an inadequate response to other antiepileptic drugs.